Brodalumab治疗中轴型脊柱关节炎的3期试验16周结果
这项多中心、安慰剂对照3期研究纳入日本、韩国和台湾的axSpA患者,随机接受brodalumab 210 mg或安慰剂治疗16周。brodalumab组ASAS 40应答率显著高于安慰剂组(43.8% vs 24.1%,率差19.7%,p=0.018),安全性与此前银屑病研究一致。
要点
- brodalumab 210 mg组16周ASAS 40应答率43.8%,安慰剂组24.1%,率差19.7%(p=0.018)。
- ASAS 20应答率brodalumab组67.5%,安慰剂组41.8%。
- ASDAS-CRP较基线变化brodalumab组-1.127,安慰剂组-0.672。
核心结论
- brodalumab在活动性axSpA患者中第16周显示显著改善,安全性与此前全球/日本银屑病研究一致。
研究设计与样本
- 多中心、安慰剂对照3期研究(NCT02985983),在日本、韩国和台湾48个中心开展。
- axSpA患者按1:1随机接受皮下brodalumab 210 mg(n=80)或安慰剂(n=79),基线、第1、2周及此后每2周给药,双盲期16周。
主要发现
- ASAS 40应答率(n/N;95%CI)brodalumab组43.8%(35/80;32.7, 55.3),安慰剂组24.1%(19/79;15.1, 35.0),率差19.7%(5.3, 34.1),分层Cochran-Mantel-Haenszel检验p=0.018。
- ASAS 20应答率(n/N;95%CI)brodalumab组67.5%(54/80;56.1, 77.6),安慰剂组41.8%(33/79;30.8, 53.4)。
- 第16周ASDAS-CRP较基线最小二乘均值变化(95%CI):brodalumab组-1.127(-1.322, -0.931),安慰剂组-0.672(-0.872, -0.473)(基线值brodalumab 2.660,安慰剂2.716)。
- 治疗中出现的不良事件brodalumab组44例(55%),安慰剂组45例(57%)。
关键数值与推荐
- 主要终点为第16周ASAS 40应答率。
- 次要终点包括第16周ASAS 20应答率、ASDAS-CRP变化及安全性。
临床怎么用
- 对于活动性axSpA患者,brodalumab 210 mg每2周皮下给药可考虑作为改善ASAS 40应答率的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA). METHODS: In a multicentre, placebo-controlled phase 3 study (NCT02985983) conducted at 48 sites across Japan, Korea and Taiwan, patients with axSpA were randomised 1:1 to receive subcutaneous brodalumab 210 mg (n=80) or placebo (n=79) at baseline, weeks 1 and 2 and every 2 weeks thereafter, during the 16-week double-blind period. The primary endpoint was the proportion of patients with Assessment of SpondyloArthritis International Society (ASAS) 40 response at week 16. Secondary endpoints included the proportion of patients with ASAS 20 response and change in Ankylosing Spondylitis Disease Activity Score using C-reactive protein (ASDAS-CRP) at week 16 and safety. RESULTS: ASAS 40 response rate (n/N; 95% CI) was 43.8% (35/80; 32.7, 55.3) with brodalumab vs 24.1% (19/79; 15.1, 35.0) with placebo (rate difference, 19.7% (5.3, 34.1); p=0.018 by stratified Cochran-Mantel-Haenszel test). ASAS 20 response rate (n/N; 95% CI) was 67.5% (54/80; 56.1, 77.6) vs 41.8% (33/79; 30.8, 53.4) and least squares mean change (95% CI) from baseline (brodalumab, 2.660; placebo, 2.716) in ASDAS-CRP was -1.127 (-1.322, -0.931) with brodalumab vs -0.672 (-0.872, -0.473) with placebo at week 16. Treatment-emergent adverse events were reported in 44 (55%) and 45 (57%) patients in the brodalumab and placebo groups, respectively. CONCLUSION: Brodalumab demonstrated a significant improvement at week 16 in patients with active axSpA. Safety of brodalumab was consistent with that reported in previous global/Japanese psoriasis studies.
引用
- Wei JC, Kim TH, Kishimoto M, et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann Rheum Dis. 2021. PMID: 33827787. doi:10.1136/annrheumdis-2020-219406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。